Johnson & Johnson Inventory 2010-2024 | JNJ
Johnson & Johnson inventory from 2010 to 2024. Inventory can be defined as the total value of inventories in all stages of completion.
- Johnson & Johnson inventory for the quarter ending September 30, 2024 was $12.603B, a 12.55% increase year-over-year.
- Johnson & Johnson inventory for 2023 was $11.181B, a 8.89% increase from 2022.
- Johnson & Johnson inventory for 2022 was $10.268B, a 1.15% decline from 2021.
- Johnson & Johnson inventory for 2021 was $10.387B, a 11.16% increase from 2020.
Johnson & Johnson Annual Inventory
(Millions of US $) |
| 2023 |
$11,181 |
| 2022 |
$10,268 |
| 2021 |
$10,387 |
| 2020 |
$9,344 |
| 2019 |
$9,020 |
| 2018 |
$8,599 |
| 2017 |
$8,765 |
| 2016 |
$8,144 |
| 2015 |
$8,053 |
| 2014 |
$8,184 |
| 2013 |
$7,878 |
| 2012 |
$7,495 |
| 2011 |
$6,285 |
| 2010 |
$5,378 |
| 2009 |
$5,180 |
Johnson & Johnson Quarterly Inventory
(Millions of US $) |
| 2024-09-30 |
$12,603 |
| 2024-06-30 |
$12,169 |
| 2024-03-31 |
$11,383 |
| 2023-12-31 |
$11,181 |
| 2023-09-30 |
$11,198 |
| 2023-06-30 |
$12,888 |
| 2023-03-31 |
$12,809 |
| 2022-12-31 |
$10,268 |
| 2022-09-30 |
$11,675 |
| 2022-06-30 |
$11,437 |
| 2022-03-31 |
$10,990 |
| 2021-12-31 |
$10,387 |
| 2021-09-30 |
$10,387 |
| 2021-06-30 |
$10,100 |
| 2021-03-31 |
$9,952 |
| 2020-12-31 |
$9,344 |
| 2020-09-30 |
$9,599 |
| 2020-06-30 |
$9,424 |
| 2020-03-31 |
$8,868 |
| 2019-12-31 |
$9,020 |
| 2019-09-30 |
$9,173 |
| 2019-06-30 |
$9,263 |
| 2019-03-31 |
$9,086 |
| 2018-12-31 |
$8,599 |
| 2018-09-30 |
$8,678 |
| 2018-06-30 |
$8,810 |
| 2018-03-31 |
$9,014 |
| 2017-12-31 |
$8,765 |
| 2017-09-30 |
$9,521 |
| 2017-06-30 |
$9,699 |
| 2017-03-31 |
$8,878 |
| 2016-12-31 |
$8,144 |
| 2016-09-30 |
$8,488 |
| 2016-06-30 |
$8,523 |
| 2016-03-31 |
$8,170 |
| 2015-12-31 |
$8,053 |
| 2015-09-30 |
$8,206 |
| 2015-06-30 |
$8,298 |
| 2015-03-31 |
$8,085 |
| 2014-12-31 |
$8,184 |
| 2014-09-30 |
$8,419 |
| 2014-06-30 |
$8,155 |
| 2014-03-31 |
$8,009 |
| 2013-12-31 |
$7,878 |
| 2013-09-30 |
$8,124 |
| 2013-06-30 |
$7,822 |
| 2013-03-31 |
$7,691 |
| 2012-12-31 |
$7,495 |
| 2012-09-30 |
$7,809 |
| 2012-06-30 |
$7,697 |
| 2012-03-31 |
$6,800 |
| 2011-12-31 |
$6,285 |
| 2011-09-30 |
$6,428 |
| 2011-06-30 |
$6,413 |
| 2011-03-31 |
$6,200 |
| 2010-12-31 |
$5,378 |
| 2010-09-30 |
$5,409 |
| 2010-06-30 |
$5,071 |
| 2010-03-31 |
$5,308 |
| 2009-12-31 |
$5,180 |
| 2009-09-30 |
$5,568 |
| 2009-06-30 |
$5,472 |
| 2009-03-31 |
$5,359 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$368.366B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
